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Summary Introduction BAY 56-3722 (formerly BAY 38-
3441) is a glycoconjugated campthotecin, which was
considered an attractive drug to assess in colorectal cancer
(CRC). Patient and methods Phase II study design
evaluating the antitumor activity of BAY 56-3722 IV
320 mg/m
2 daily for 3 days every 3 weeks in patients with
recurrent or metastatic inoperable CRC resistant to irinote-
can. Results Twenty-four patients received the study
treatment. Triggered by adverse events in two other studies
with this compound the study was put on a clinical hold
while the safety data were reviewed for the entire program.
After the review Bayer decided to withdraw BAY 56-3722
from all clinical investigations. Discussion We felt it was
our obligation to share this interrupted phase II study for
two reasons: to report the fate of camptothecin glycoconju-
gate and to report the unique situation of a clinical hold
during a phase II study.
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Introduction
Since more than a decade the topoisomerase I inhibitor
irinotecan has been one of the most important drugs in the
treatment of metastatic CRC although its single agent activity
in second line is only 20% and its toxicity is considerable [1].
Especially in the pre-cetuximab/panitumab and bevacizumab
era new camptotecin analogues with improved activity and
less toxicity were therefore warranted. BAY 56-3722
(formerly BAY 38-3441) is a camptothecin glycoconjugate
that generates camptothecin upon cleavage. BAY 56-3722
consists of a carbohydrate (fucose) moiety attached to the
camptothecin toxophore by a peptide spacer. The campto-
thecin delivered from BAY 56-3722 acts by binding to and
stabilizing the topoisomerase-I-DNA complex, leading to an
accumulation of double-stranded DNA breaks upon replica-
tion, ultimately causing cell death. The lactone form is
associated with its antitumor activity, whereas the carboxyl-
ate form is inactive [2, 3].
BAY 56-3722 was considered an attractive drug to
assess in CRC. First, there were in vitro data suggesting the
utility of BAY 56-3722 in a variety of CRC lines. Secondly,
the two main body tissues with highest levels of radioac-
tivity after administration of BAY 56-3722 were liver
(3.0%) and the large intestine (3.6%). This could provide a
potential advantage for BAY 56-3722 over other chemo-
therapy agents in patients with metastatic tumors in the
liver. BAY 56-3722 was evaluated in vivo in a panel of
human tumor xenografts in nude mice [4]. In most of these
experiments, BAY 56-3722 was tested in comparison with
doses of topotecan and not with irinotecan, which would have
been more appropriate. BAY 56-3722 was more efficacious at
maximum tolerated dose than topotecan and exhibited less
gastrointestinal toxicity and myelosuppression. In patients
BAY56-3722hasbeenstudiedonthreeschedules,onceevery
21 days, daily for 3 days every 21 days and daily for 5 days
every 21 days [3, 5, 6]. In the phase I study where a daily ×5
schedule is explored, there appears to be a 4-fold increase in
the camptothecin AUC comparing day 1 to day 5 suggesting
that this schedule might be the most likely schedule to have
antitumor activity [5].
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beginning of this century to study the antitumor activity,
safety and tolerability of BAY 56-3722 using a daily
schedule for 3 days every 3 weeks.
Patients and methods
The study was conducted at 13 centers in Canada, the USA
and the Netherlands. Patients received BAY 56-3722 IV
over 30 min daily for 3 days every 3 weeks until objective
evidence of tumor progression, unacceptable toxicity,
consent withdrawn or until the investigator deemed that
continuation of treatment adds no more benefit for the
patient.
Tumor response measurements were made according to
WHO criteria at baseline and every 6 weeks for the entire
duration of treatment [7].
The study was planned to enroll a maximum of 140
evaluable patients. A three stage enrolment procedure
would be used (null hypothesis: underlying response rate
is less than or equal to 10%; alternative hypothesis: true
response rate is more than or equal to 20%; one-sided alpha
of 0.025; power of 90%). A futility analysis was planned
when 20 evaluable patients were treated and followed for
tumor response for a maximum of six cycles. If none of
these patients responded (no PR or CR) to therapy
termination of the study was warranted. If at least one
patient responded (5%), an additional 60 patients were
planned to be enrolled. The second futility analysis would
count the number of responders out of the 80 patients at the
end of maximum six cycles: if the number of responders
would be less than 10% the likelihood of success would be
sufficiently low to warrant discontinuation of the study. If
the number of responders would be more than 20% the
regimen would be considered active and the study might be
closed in preparation for Phase III. Nevertheless, if 9–15
responders were obtained, additional 60 patients would be
enrolled and response rate would be evaluated at the end of
cycle 6 to determine if the drug was active enough to start
Phase III.
Adverse events were graded by the National Cancer
Institute (NCI) Common Toxicity Criteria (CTC) version
2.0 [8].
Informed consent and protocol were reviewed and
approved by the appropriate local ethics or review boards
before study initiation.
Patients were considered eligible if they had histologi-
cally confirmed recurrent or metastatic colorectal cancer
with documented progression during or within 6 months
after treatment with irinotecan. Required were adequate
bone marrow, renal and liver functions and signed informed
consent.
Results
Twenty-five patients were enrolled in this study. Twenty-four
patients receivedatleast one doseofstudy treatmentand were
thereforeincludedinthesafetyevaluation.Onepatientdidnot
qualifytoreceivestudymedicationduetoaprotocolinclusion
criteria violation.
Of the 24 patients in the safety population, 18 (75%)
discontinued study treatment because of disease progres-
sion, 4 (17%) because of consent withdrawn, and 2 (8%)
because of study termination by the sponsor. Of the four
patients that withdrew consent, one withdrew it after only
one dose of study drug, another one after cycle 1, a third
patient due to opting for treatment with capecitabine, and
the last patient due to clinical deterioration.
The futility analysis that was planned for this study after
the first 20 eligible patients were enrolled could not be
completed due to an initial clinical hold as well as later
discontinuation of the BAY 56-3722 development program.
This study was put on a clinical hold while the safety
data were reviewed for the entire BAY 56-3722 develop-
ment program. This review was triggered by events in two
other studies in the program. Once this review was
completed, the clinical hold was removed (after 5 weeks).
At the time of the clinical hold, only two patients were
taken off study because of lack of the essential IRB
approval to go through. At the time when the clinical hold
was removed, patients had to undergo a new tumor
assessment and show no disease progression in order to
continue study drug treatment. Only one patient qualified;
that patient received two additional cycles of treatment.
At least one treatment-emergent event was reported by
23 of the 24 patients (96%). One patient with non-insulin
dependent diabetes and coagulant use experienced one
episode each of grade 4 rectal bleeding and hypoglycemia.
Grade 3 non-hematological adverse events were experi-
enced by eight patients. Three patients experienced a total
of four adverse events that were considered serious. Two
of these events, grade 2 creatinine elevation and grade 3
renal/genitourinary-other (bilateral hydronephrosis), were
considered possibly drug related. All four serious adverse
events resolved. No patients developed grade 4 hemato-
logical or biochemical toxicities. Three patients had grade
3 toxicities.
Discussion
Development in systemic therapy options for CRC is
moving fast. This study was conducted in the pre-
cetuximab/panitumab and bevacizumab era. BAY 56-
3722, selected for this phase II study, was a promising
drug in diseases that were resistant to other topisomerase I
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lactone moiety of the drug with enhanced pre-clinical
antitumor activity and a favorable toxicity profile. Based
on three phase I studies further phase II studies in several
tumor types were undertaken with the preferred BAY-56-
3722 regimen. None of these studies have been published
and we felt that this was an omission. Therefore we decided
to share our results and the fate of this drug in the current
publication. This study was put on a clinical hold while the
safety data were reviewed for the entire program, because
of excessive toxicity in three patients with hepatocellular
carcinoma in two studies in the program, this study not
being one of them. Since, after review, this toxicity
appeared to be disease related, patients were allowed to
continue treatment after 4 weeks provided that there was no
disease progression in our study. During the clinical hold
for toxicity reasons Bayer undertook a voluntary action to
withdraw camptothecin glycoconjugate (BAY 56-3722,
formerly BAY 38-3441) from further clinical development
due to observed safety issues, lack of therapeutic benefit,
and poor enrolment in other studies. Due to this decision
we were not able to draw conclusions whether this drug is
active or not in colorectal cancer. Prematurely stopped
studies as a result of a decision of the sponsor not to further
develop a study drug (based on results in other studies) are
extremely rare and the (temporary) withdrawal of the drug
during the study puts the patient and the treating physician/
local study team in a difficult position. The clinical hold
was undertaken for safety reasons in the first place which is
easier to accept than for economic reasons. We felt it was
our obligation to share this interrupted phase II study for
two reasons: to report the fate of camptothecin glycoconju-
gate and to report the unique situation of a clinical hold
during a phase II study.
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